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A bs tr ac t
Background
Myocardial fibrosis is a hallmark of hypertrophic cardiomyopathy and a proposed 
substrate for arrhythmias and heart failure. In animal models, profibrotic genetic 
pathways are activated early, before hypertrophic remodeling. Data showing early 
profibrotic responses to sarcomere-gene mutations in patients with hypertrophic 
cardiomyopathy are lacking.
Methods
We used echocardiography, cardiac magnetic resonance imaging (MRI), and serum 
biomarkers of collagen metabolism, hemodynamic stress, and myocardial injury to 
evaluate subjects with hypertrophic cardiomyopathy and a confirmed genotype.
Results
The study involved 38 subjects with pathogenic sarcomere mutations and overt 
hypertrophic cardiomyopathy, 39 subjects with mutations but no left ventricular 
hypertrophy, and 30 controls who did not have mutations. Levels of serum C-termi-
nal propeptide of type I procollagen (PICP) were significantly higher in mutation 
carriers without left ventricular hypertrophy and in subjects with overt hypertrophic 
cardiomyopathy than in controls (31% and 69% higher, respectively; P<0.001). The 
ratio of PICP to C-terminal telopeptide of type I collagen was increased only in 
subjects with overt hypertrophic cardiomyopathy, suggesting that collagen synthe-
sis exceeds degradation. Cardiac MRI studies showed late gadolinium enhance-
ment, indicating myocardial fibrosis, in 71% of subjects with overt hypertrophic 
cardiomyopathy but in none of the mutation carriers without left ventricular hyper-
trophy.
Conclusions
Elevated levels of serum PICP indicated increased myocardial collagen synthesis in 
sarcomere-mutation carriers without overt disease. This profibrotic state preceded 
the development of left ventricular hypertrophy or fibrosis visible on MRI. (Funded 
by the National Institutes of Health and others.)
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Hypertrophic cardiomyopathy is caused by mutations in genes encoding sarcomere proteins.1,2 With a prevalence 
of approximately 1 case per 500 persons in the 
general population, hypertrophic cardiomyopa-
thy is the most common monogenic cardiac dis-
order.3 The clinical diagnosis depends on the 
identification of unexplained left ventricular hy-
pertrophy, but this finding is present only in per-
sons with established disease and is typically ab-
sent in childhood.4 In contrast, genetic diagnosis 
identifies pathogenic sarcomere mutations in per-
sons at any age, including mutation carriers with 
overt hypertrophic cardiomyopathy and mutation 
carriers without hypertrophy who are at high risk 
for the development of disease. Studying such 
mutation carriers may provide insight into the 
pathophysiology of hypertrophic cardiomyopathy 
by revealing subtle, early manifestations of sar-
comere mutations that precede the obvious patho-
logic remodeling of overt disease. For example, 
left ventricular relaxation is impaired in muta-
tion carriers without left ventricular hypertrophy, 
indicating that sarcomere mutations directly af-
fect diastolic function.5-7
Myocardial fibrosis, a hallmark of hypertro-
phic cardiomyopathy, is thought to contribute to 
sudden cardiac death, ventricular tachyarrhyth-
mias, left ventricular dysfunction, and heart fail-
ure.8-12 Histologic evaluation universally reveals 
increased interstitial and focal myocardial fibro-
sis in overt disease. In most patients with overt 
hypertrophic cardiomyopathy, dense focal fibro-
sis can also be visualized noninvasively with the 
use of gadolinium-enhanced cardiac magnetic 
resonance imaging (MRI).10,13-18 The trigger for 
increased myocardial fibrosis in hypertrophic 
cardiomyopathy remains unclear, but it has been 
attributed both to premature myocyte death 
caused by stresses imposed directly by sarcomere 
mutations19-22 and to later pathologic changes, 
including intracavitary obstruction, small-vessel 
disease, and ischemia.9,12,23 Animal models of 
hypertrophic cardiomyopathy that recapitulate 
human disease24 have recently shed light on 
the earliest cellular and molecular responses to 
sarcomere-gene mutations.25 Cardiac transcrip-
tional profiling in young mice in which hyper-
trophy has not yet developed shows activation of 
pathways involved in fibrosis and collagen depo-
sition.25 These studies indicate that a profibrotic 
milieu is present early in hearts with hypertro-
phic cardiomyopathy, even when cardiac histo-
logic findings are normal.
Biomarkers of collagen synthesis and degrada-
tion reflect collagen metabolism. The C-terminal 
propeptide of type I procollagen (PICP) is released 
in a 1:1 ratio during the synthesis of type I col-
lagen from its precursor, procollagen type I,26 
and serum levels reliably reflect myocardial type I 
collagen synthesis.27 Increased serum PICP lev-
els correlate with adverse outcomes in hyperten-
sion, heart failure, and myocardial infarction.28-30
There have been few studies of these biomark-
ers in hypertrophic cardiomyopathy, although 
preliminary studies of nongenotyped patients 
with overt disease suggest that collagen turnover 
is increased.31-34 Data regarding collagen metabo-
lism in patients with early disease are lacking. 
We therefore measured serum biomarkers of 
collagen metabolism to assess profibrotic pro-
cesses in a genotyped population with hypertro-
phic cardiomyopathy, comparing mutation carri-
ers in whom left ventricular hypertrophy had not 
yet developed with those who had overt disease 
and with mutation-negative normal controls.
Me thods
Study Population
Genotyped patients with hypertrophic cardio-
myopathy and their relatives, identified through 
research studies or clinical evaluation, were re-
cruited and assigned to one of three groups. Muta-
tion carriers with a left ventricular wall thickness 
of 12 mm or greater (in adults) or a z score of 
2 or more (in children)35 were classified as hav-
ing overt hypertrophic cardiomyopathy. Healthy 
mutation carriers who did not meet these criteria 
were classified as mutation carriers without left 
ventricular hypertrophy. The criteria we used are 
more rigorous than those used clinically to diag-
nose hypertrophic cardiomyopathy.36 They were 
chosen to avoid the inclusion of subjects with 
borderline left ventricular hypertrophy and po-
tentially emerging or mild cardiomyopathy in the 
group of mutation carriers without left ventricu-
lar hypertrophy. Control subjects were healthy, 
mutation-negative relatives at ages similar to those 
of mutation carriers without left ventricular hy-
pertrophy.
The study protocol was approved by the insti-
tutional review boards of Brigham and Women’s 
Hospital and Children’s Hospital Boston, and the 
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study was conducted in accordance with the pro-
tocol. Written informed consent was obtained 
from all participants or their parents or legal 
guardians.
Subjects with systemic hypertension (defined 
by systolic blood pressure ≥140 mm Hg, diastolic 
blood pressure ≥90 mm Hg, or use of antihyper-
tensive medication), coronary artery disease, valvu-
lar heart disease, previous septal myectomy, alco-
hol septal ablation, electronic ventricular pacing, 
or atrial fibrillation were excluded. Subjects with 
other conditions that might influence collagen 
metabolism (e.g., surgery or trauma within the 
previous 6 months, known fibrotic or inflam-
matory disease, or cancer) were also excluded.
Echocardiography
Transthoracic echocardiograms were obtained 
with the use of a Vivid 7 ultrasonography system 
(General Electric Medical Systems). The average 
of three cardiac cycles was used for measure-
ments of cardiac dimensions, mitral inflow pat-
terns, and the left ventricular ejection fraction 
(calculated according to Simpson’s method).37 
Myocardial velocities during systole and early di-
astole were measured by means of tissue Doppler 
imaging at the lateral, septal, anterior, and infe-
rior aspects of the mitral annulus in the apical 
four-chamber and two-chamber views. Global 
values of systolic and early diastolic myocardial 
velocities were calculated as the average of these 
four measurements to represent myocardial con-
traction and relaxation, respectively. The ratio of 
early mitral inflow velocity to global early dia-
stolic velocity approximately represented left ven-
tricular end-diastolic pressure.38 Measures of left 
ventricular stiffness were evaluated, including 
E-wave deceleration time, end-systolic elastance 
([0.9 × systolic blood pressure] ÷ left ventricular 
end-systolic volume), and stiffness (70 ÷ [E-wave 
deceleration time −20])2 or (E-wave deceleration 
time ÷ early mitral inflow velocity).39,40 Images 
were analyzed by two observers who were un-
aware of the subjects’ clinical and genetic status.
Cardiac MRI
Cardiac MRI studies were performed in a sub-
group of subjects with overt hypertrophic cardio-
myopathy and in mutation carriers without left 
ventricular hypertrophy, with the use of a 1.5-T 
cardiac MRI system (HDX Excite II, General Elec-
tric) or a 3.0-T system (Magnetom Trio, Siemens). 
Steady-state free precession of cine images was 
used to quantify left ventricular function (short-
axis stack, slice thickness of 8 mm) and myocar-
dial mass by means of standard criteria.41 Seg-
mented inversion-recovery fast gradient−echo 
imaging was used to assess late gadolinium en-
hancement 10 minutes after the administration 
of gadolinium diethylenetriamine pentaacetic acid 
at a dose of 0.15 mmol per kilogram of body 
weight. The extent of late gadolinium enhance-
ment was quantified by planimetric assessment 
of all short-axis slices for total volume (the sum 
of the areas measured, in grams) and as a pro-
portion of the total left ventricular mass (the per-
centage of late gadolinium enhancement). Late 
gadolinium enhancement was defined as 2 stan-
dard deviations above the mean signal intensity 
of the distant myocardium.42 Images were ana-
lyzed offline with the use of QMass MR software 
(Medis) by two observers who were unaware of 
the subjects’ clinical and genetic information.
Measurement of Serum Biomarkers
Blood samples (serum and plasma) were obtained 
at the time of cardiac imaging, processed within 
60 minutes after phlebotomy, and stored at −80°C 
before analysis of PICP, matrix metalloproteinase 
1 (MMP-1), tissue inhibitor of metalloproteinase 
1 (TIMP-1), C-terminal telopeptide of type I col-
lagen (CITP), osteopontin, bone-specific alkaline 
phosphatase, N-terminal propeptide of B-type 
natriuretic peptide, B-type natriuretic peptide, 
and cardiac troponin I. All assays were performed 
with the use of commercially available reagents 
(see the Methods section in the Supplementary 
Appendix, available with the full text of this article 
at NEJM.org) by investigators who were unaware 
of the subjects’ clinical and genetic status.
Statistical Analysis
To test for differences among the three groups 
and between subjects with β-myosin heavy 
chain (MYH7) mutations and those with cardiac 
myosin-binding protein C (MYBPC3) mutations, 
analysis of variance and logistic regression were 
performed with clustering to adjust for family 
relationships, assuming an exchangeable corre-
lation structure. Age-dependent mitral inflow, 
myocardial velocities measured by tissue Doppler 
imaging, and biomarker patterns were adjusted 
for age; biomarkers were also adjusted for sex. 
Values are expressed as adjusted means ±SE. 
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Bonferroni-corrected P values of less than 0.017 
were considered to indicate statistical signifi-
cance for multiple comparisons across the three 
groups. Pearson’s correlation was used to evalu-
ate associations between continuous measures. 
Analyses were performed with the use of SAS 
software, version 9.1 (SAS Institute).
R esult s
Clinical Characteristics
Study procedures were performed in 107 subjects. 
Forty-two different pathogenic mutations7 (37 
MYH7, 31 MYBPC3, 9 cardiac troponin T [TNNT2], 
and 1 α-tropomyosin [TPM1]) were identified in 
47 families with hypertrophic cardiomyopathy 
(Table 1 in the Supplementary Appendix).
On the basis of clinical evaluations and geno-
types, 38 subjects were classified as mutation 
carriers with overt hypertrophic cardiomyopathy, 
39 as mutation carriers without left ventricular 
hypertrophy, and 30 as having neither mutations 
nor hypertrophic cardiomyopathy (control sub-
jects) (Table 1). Mutation carriers without left 
ventricular hypertrophy and control subjects were 
of similar age, were asymptomatic, were not re-
ceiving cardiac medications, and had normal 
cardiac dimensions. These subjects had slightly 
lower blood pressure than controls, and they 
also had a higher left ventricular ejection frac-
tion and a lower global early diastolic myocar-
dial velocity, as reported previously for such 
carriers.6,7
Subjects with overt hypertrophic cardiomyo-
pathy had a significantly greater left ventricular 
wall thickness (76% with asymmetric septal hy-
pertrophy), smaller left ventricular cavity, and 
larger left atrial diameter than mutation carriers 
without left ventricular hypertrophy and control 
subjects. Sixteen percent had intracavitary obstruc-
tion at rest (peak gradient, ≥30 mm Hg). Symp-
toms were generally mild in subjects with overt 
hypertrophic cardiomyopathy (74% had New 
York Heart Association [NYHA] class I status 
and 21% had NYHA class II status). Three sub-
jects had NYHA class III symptoms, including 
two subjects with end-stage hypertrophic cardio-
myopathy, defined by a reduced left ventricular 
ejection fraction (<50%). Sixty-eight percent of 
the subjects with overt hypertrophic cardiomyo-
pathy were receiving cardioactive medications, 
including eight subjects receiving angiotensin-
converting−enzyme (ACE) inhibitors, angiotensin-
receptor blockers (ARBs), or spironolactone.
imaging of Fibrosis with cardiac mri
Cardiac MRI studies with the administration of 
gadolinium were performed in 28 subjects with 
overt hypertrophic cardiomyopathy and 32 mu-
tation carriers without left ventricular hypertro-
phy. Studies were not performed in 9 subjects 
with overt hypertrophic cardiomyopathy who had 
implantable cardioverter−defibrillators and in 
5 mutation-positive children without left ventric-
ular hypertrophy whose parents declined. In 3 sub-
jects, gadolinium was not administered. Late 
gadolinium enhancement was present in 71% of 
subjects with overt hypertrophic cardiomyopathy 
but in none of the mutation carriers without left 
ventricular hypertrophy (Fig. 1). The extent of 
late gadolinium enhancement in subjects with 
overt hypertrophic cardiomyopathy ranged from 
0 to 55% of the total left ventricular mass (mean, 
14.7±16.9%). There were significant correlations 
between the extent of late gadolinium enhance-
ment in these subjects and the left ventricular 
mass, ejection fraction, global early diastolic 
myocardial velocity, and ratio of early mitral in-
flow velocity to early diastolic velocity (Tables 2 
and 3 in the Supplementary Appendix). There 
were no significant correlations between late 
gadolinium enhancement and levels of cardiac 
troponin I, B-type natriuretic peptide, PICP, CITP, 
MMP-1, or TIMP-1; age; left ventricular hypertro-
phy; size of the left atrium; or E-wave decelera-
tion time.
Increased Myocardial Collagen Synthesis 
Analyses of serum biomarkers were performed 
after exclusion of the eight subjects with overt 
hypertrophic cardiomyopathy who were receiving 
ACE inhibitors, ARBs, or spironolactone (includ-
ing the two subjects with end-stage hypertrophic 
cardiomyopathy), since these factors may influ-
ence collagen metabolism. As compared with 
PICP levels in controls (82.16±3.03 μg per liter), 
the PICP levels were significantly elevated in mu-
tation carriers without left ventricular hypertro-
phy (107.73±4.65 μg per liter, a 31% elevation) 
and in subjects with overt hypertrophic cardio-
myopathy (138.70±11.63 μg per liter, a 69% ele-
vation; P<0.001 for both comparisons with con-
trols) (Table 2 and Fig. 1 in the Supplementary 
Appendix). PICP was the only biomarker that dif-
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fered between mutation carriers and noncarriers 
(Table 2). Among all family members with a nor-
mal left ventricular wall thickness, the odds of 
carrying a mutation increased by 50% for every 
increase in PICP of 10 μg per liter, after adjust-
ment for age, sex, early diastolic myocardial ve-
locity, and left ventricular ejection fraction (odds 
ratio, 1.50; 95% confidence interval [CI], 1.18 to 
1.91; P = 0.001).
Type I collagen is a major component of bone; 
therefore, PICP levels may reflect bone forma-
tion, particularly in growing children and ado-
A
RV
RA
LA
LV
RV
RA
LA
LV
RV
LV
RV
LV
RV
LV
RV
LV
B
DC
FE
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lescents.43 To minimize such confounding, we 
measured levels of bone-specific alkaline phos-
phatase (a specific marker of bone metabolic 
activity)43 and the ratio of PICP to bone-specific 
alkaline phosphatase to adjust PICP levels for the 
influence of bone collagen turnover. As com-
pared with levels of bone-specific alkaline phos-
phatase in controls, levels were 17% lower in 
mutation carriers without left ventricular hyper-
trophy (P = 0.003) and were 20% lower in subjects 
with overt hypertrophic cardiomyopathy (P = 0.006) 
(Fig. 1B in the Supplementary Appendix). The ra-
tio of PICP to bone-specific alkaline phosphatase 
was significantly higher both in mutation carri-
ers without left ventricular hypertrophy and in 
subjects with overt hypertrophic cardiomyopathy 
than in controls (77% higher in mutation carri-
ers but no left ventricular hypertrophy, P<0.001) 
(Fig. 1C in the Supplementary Appendix). These 
results suggest that elevated PICP levels in sar-
comere-mutation carriers reflect increased myo-
cardial collagen synthesis rather than increased 
bone metabolic activity.
No significant differences in markers of colla-
gen degradation (MMP-1, TIMP-1, and CITP) were 
identified in isolation. The PICP:CITP ratio reflects 
the balance between collagen synthesis and deg-
radation.44 As compared with the PICP:CITP ratio 
in control subjects, the ratio was unchanged in 
mutation carriers without left ventricular hyper-
trophy but significantly higher in subjects with 
overt hypertrophic cardiomyopathy, suggesting 
that collagen synthesis exceeds degradation in 
established disease.
Clinical and Genetic Associations  
with Increased PICP Levels
No significant correlations were identified between 
increased PICP levels and levels of B-type natri-
uretic peptide, N-terminal propeptide of B-type 
natriuretic peptide, or cardiac troponin I; the 
degree of left ventricular hypertrophy; left ven-
tricular mass; left atrial size; left ventricular sys-
tolic or diastolic function; echocardiographic mea-
surements of left ventricular stiffness; or late 
gadolinium enhancement on cardiac MRI in any 
cohort. Among mutation carriers without left 
ventricular hypertrophy, there were also no sig-
nificant differences in mean PICP levels between 
subjects with and those without electrocardio-
graphic (ECG) abnormalities, including Q waves 
(which were present in 36% of mutation carriers 
without left ventricular hypertrophy).
We compared subjects who had MYH7 muta-
tions and those who had MYBPC3 mutations to 
assess potential genotype−phenotype correlations 
in the two most common genetic subtypes of 
hypertrophic cardiomyopathy (Table 3). PICP lev-
els were 14% higher in subjects without left 
ventricular hypertrophy who had MYH7 mutations 
than in subjects without left ventricular hyper-
trophy who had MYBPC3 mutations (P = 0.014). 
Global early myocardial diastolic velocities were 
15% lower in subjects without left ventricular 
hypertrophy who had MYH7 mutations (P = 0.002) 
than in those who had MYBPC3 mutations, in 
whom the velocities were essentially normal. 
Among subjects with overt hypertrophic cardio-
myopathy, PICP levels did not differ significantly 
between those who had MYH7 mutations and 
those who had MYBPC3 mutations, although early 
myocardial diastolic velocities were lower in sub-
jects with MYH7 mutations.
Discussion
We present data showing increased myocardial 
type I collagen synthesis in both early and es-
tablished hypertrophic cardiomyopathy. Elevat-
ed serum PICP levels in mutation carriers with 
normal cardiac morphologic features constitute 
a potentially useful phenotype for sarcomere 
mutations and a serologic marker of genetic 
risk that can be detected before clinical diagno-
sis. These observations offer insights into the 
pathophysiology of hypertrophic cardiomyopa-
thy, suggesting that the stimulus for myocardial 
Figure 1 (facing page). Gadolinium-Enhanced Cardiac 
MRI Scans in MYH7 Mutation Carriers with and Those 
without Overt Hypertrophic Cardiomyopathy.
Panels A, C, and E show no morphologic abnormalities 
suggestive of hypertrophic cardiomyopathy in a carrier 
of a myosin heavy-chain missense mutation. Left ven-
tricular hypertrophy and late gadolinium enhancement 
are absent. Panels B, D, and F show typical findings of 
hypertrophic cardiomyopathy in a relative of the subject 
in Panels A, C, and E with overt disease caused by the 
same myosin heavy-chain mutation. These findings in-
clude a markedly thickened septum (Panel B, arrow) 
associated with areas of heterogeneous late gadolinium 
enhancement, which affects 17% of the total left ven-
tricular mass and involves the anteroseptum (Panel D, 
arrows) and the inferoseptum (Panels D and F, arrows). 
LA denotes left atrium, LV left ventricle, RA right atrium, 
and RV right ventricle.
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fibrosis is an early manifestation of sarcomere-
gene mutations.
In contrast to collagen synthesis, biomarkers 
of collagen degradation in isolation were not in-
formative regarding genotype or clinical status. 
However, the PICP:CITP ratio, an index of the 
dynamic equilibrium between collagen type I syn-
thesis and degradation,44 was unchanged in mu-
tation carriers without left ventricular hypertro-
phy but increased in subjects with overt disease. 
We propose that sarcomere mutations trigger an 
early increase in collagen synthesis that is ini-
tially balanced by degradation, thereby limiting 
fibrogenesis. In overt hypertrophic cardiomyop-
athy, synthesis exceeds degradation, resulting in 
frank myocardial fibrosis. Although our study 
was not longitudinal, these results are consistent 
with the natural history of hypertrophic cardio-
myopathy and suggest that collagen accumula-
tion increases as disease develops. Indeed, these 
findings may partially explain why late gado-
linium enhancement on cardiac MRI was present 
in the majority of our subjects with overt hyper-
trophic cardiomyopathy, as observed in other 
studies,10,13,14,16-18 but absent in the mutation car-
riers without left ventricular hypertrophy, despite 
elevated PICP levels.
Increased myocardial fibrosis is a hallmark of 
overt hypertrophic cardiomyopathy and is fre-
quently interpreted as a secondary response to 
the pathophysiological remodeling of long-stand-
ing disease, including ischemia, obstruction, and 
microvascular abnormalities.9,12,23 This interpre-
tation is challenged by studies showing early 
activation of profibrotic genetic pathways in a 
mouse model of hypertrophic cardiomyopathy. 
In young mice with a myosin heavy-chain muta-
tion, comprehensive transcriptional profiling re-
vealed increased expression of genes that drive 
extracellular-matrix formation before fibrosis or 
left ventricular hypertrophy develops.25 RNA lev-
els of connective-tissue growth factor, periostin, 
transforming growth factor β1 and β2, fibronec-
tin, and type I collagen were increased despite 
normal cardiac histologic findings.
Our data translate these findings from mouse 
models to human disease, providing further evi-
dence that fibrosis is a fundamental, early con-
sequence of sarcomere mutations. On the basis 
of the elevated PICP levels in mutation carriers 
without left ventricular hypertrophy, we propose 
that increased collagen synthesis contributes to 
the emergence of the pathophysiological changes 
that characterize overt hypertrophic cardiomyo-
pathy. Analysis of additional biomarkers (collagen 
type III−derived peptides, other matrix metallo-
proteinases, and TIMPs) may provide a more 
comprehensive picture of how sarcomere muta-
tions affect the complex and dynamic nature of 
fibrillar collagen metabolism.
We could not identify significant correlations 
between biomarker levels and other clinical vari-
ables, including late gadolinium enhancement 
Table 3. Comparison of MYH7 and MYBPC3 Mutations.*
Variable MYH7 MYBPC3 P Value
Overt hypertrophic cardiomyopathy
No. of subjects 17 16
Age — yr 36.9±3.5 44.7±2.6 0.07
Sex — no. (%) 0.64
Male 11 (65) 9 (56)
Female 6 (35) 7 (44)
Maximal left ventricular wall thickness 
— mm
20.5±1.35 21.2±1.4 0.72
Left ventricular mass on cardiac  
MRI — g
186.8±19.3 147.2±9.8 0.07
Global early diastolic velocity —  
cm/sec
6.9±0.5 9.3±0.4 <0.001
Left ventricular ejection fraction — % 70±2 69±2 0.79
Late gadolinium enhancement  
volume — g
30.8±10.3 18.8±7.0 0.35
Late gadolinium enhancement — % 
of total left ventricular mass
18.9±6.6 11.7±4.2 0.39
PICP — μg/liter 123.01±9.28 124.16±1.07 0.91
MMP-1 — ng/ml 8.37±2.23 8.70±2.18 0.92
Mutation-positive, LVH-negative
No. of subjects 19 15
Age — yr 18.2±3.4 21.0±3.6 0.57
Sex — no. (%) 0.32
Male 8 (42) 4 (27)
Female 11 (58) 11 (73)
Global early diastolic velocity — cm/
sec
12.9±0.5 15.1±0.5 0.002
Left ventricular ejection fraction — % 71±1 69±2 0.32
PICP — μg/liter 123.51±1.20 108.10±5.06 0.014
MMP-1 — ng/ml 11.26±4.29 15.47±4.56 0.51
* Plus−minus values are means ±SE, adjusted for age. P values of less than 0.05 
were considered to indicate statistical significance; P values were adjusted for 
family relationship and age. LVH denotes left ventricular hypertrophy, MMP-1 
matrix metalloproteinase 1, MRI magnetic resonance imaging, MYBPC3 car-
diac myosin-binding protein C, MYH7 cardiac β-myosin heavy chain, and 
PICP C-terminal propeptide of procollagen type I.
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on cardiac MRI and ECG abnormalities. These 
results are not surprising, given the limited reso-
lution of late gadolinium enhancement for the 
detection of focal myocardial fibrosis (theoretical 
detection limit, approximately 0.2 g of scar; a 
clinical detection limit of approximately 2.0 g in 
infarct studies45,46) and estimates of the amount 
of scar (approximately 3% of left ventricular 
mass) needed to produce changes visible on ECG 
studies.47 Moreover, diffuse interstitial fibrosis 
is common in hypertrophic cardiomyopathy but 
cannot be visualized by means of cardiac MRI. 
In contrast, immunoassays detect micrograms of 
circulating PICP. Serum biomarkers consequent-
ly provide a more sensitive index of extracellular-
matrix remodeling and may reflect subtle chang-
es in myocardial composition and biochemical 
features that are not detectable by means of non-
invasive cardiac imaging. Notably, we observed 
that MYH7 mutation carriers without left ven-
tricular hypertrophy had both higher PICP levels 
(indicating increased collagen synthesis) and low-
er early diastolic levels (indicating more impaired 
relaxation) than MYBPC3 mutation carriers. Pre-
vious studies suggest that mutations in MYH7 re-
sult in an earlier onset of overt hypertrophic 
cardiomyopathy than do MYBPC3 mutations.48,49 
Our data provide a potential mechanism for this 
genotype−phenotype correlation — namely, that 
MYH7 mutations, as compared with MYBPC3 mu-
tations, trigger earlier extracellular-matrix re-
modeling, more extensive remodeling, or both.
The identification of increased myocardial col-
lagen synthesis in mutation carriers without left 
ventricular hypertrophy, as with diastolic dys-
function in this population,5-7 shows that sar-
comere-gene mutations have a considerable effect 
on the heart before the onset of hypertrophy. 
The detection of a profibrotic myocardial milieu 
in mutation carriers without left ventricular hyper-
trophy has intriguing clinical implications. In-
creased serologic markers of collagen synthesis 
may identify persons at risk for arrhythmias, 
sudden death, or heart failure. If so, monitoring 
levels of these markers may guide new strategies 
to attenuate disease development or adverse out-
comes in hypertrophic cardiomyopathy. We sug-
gest that incorporating genetic testing to iden-
tify at-risk mutation carriers, defining features 
of early disease, and developing therapies to 
mitigate fibrosis will foster vital new opportuni-
ties to change the natural history of hypertro-
phic cardiomyopathy.
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